Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.

ABSTRACT:

Background

Discovery and development of novel drugs that are capable of overcoming drug resistance in tumor cells are urgently needed clinically. In this study, we sought to explore whether ivermectin (IVM), a macrolide antiparasitic agent, could overcome the resistance of cancer cells to the therapeutic drugs.

Methods

We used two solid tumor cell lines (HCT-8 colorectal cancer cells and MCF-7 breast cancer cells) and one hematologic tumor cell line (K562 chronic myeloid leukemia cells), which are resistant to the chemotherapeutic drugs vincristine and adriamycin respectively, and two xenograft mice models, including the solid tumor model in nude mice with the resistant HCT-8 cells and the leukemia model in NOD/SCID mice with the resistant K562 cells to investigate the rever

SUBMITTER: Jiang L 

PROVIDER: S-EPMC6580523 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature